Canine Respiratory Coronavirus

Taxonomy and Genomic Organization of Canine Respiratory Coronavirus

Taxonomic Classification of CRCoV

Canine respiratory coronavirus (CRCoV) occupies a distinct and well-supported taxonomic position within the family Coronaviridae, subfamily Orthocoronavirinae, genus Betacoronavirus, and subgenus Embecovirus. This classification is predicated on its phylogenetic clustering with other group 2 coronaviruses, most notably bovine coronavirus (BCoV) and human coronavirus OC43 (HCoV-OC43) [1, 10, 23]. The seminal identification of CRCoV in 2003 at the Royal Veterinary College, London, arose from investigations into outbreaks of canine infectious respiratory disease (CIRD) in rehoming kennels [11, 23]. Initial sequence analysis of the polymerase and spike genes from infected tracheal and lung tissues revealed a coronavirus exhibiting 95-98% nucleotide identity with BCoV and HCoV-OC43, while displaying markedly lower similarity to the enteric canine coronavirus (CCoV) [23]. This finding fundamentally redefined the landscape of canine respiratory virology, establishing that dogs harbor a betacoronavirus distinct from the well-characterized alphacoronavirus CCoV. Subsequent phylogenetic studies have confirmed that CRCoV forms a monophyletic clade within the Betacoronavirus 1 species complex, sharing a common ancestor with BCoV and HCoV-OC43, and is now recognized as an established member of this group [14, 16, 20]. The taxonomic relationship is supported by analyses of the entire genome, as well as individual genes such as ORF1ab, hemagglutinin-esterase (HE), and spike (S), which consistently place CRCoV within the Betacoronavirus 1 cluster [1, 6, 7].

Genome Architecture and Length

The CRCoV genome is a single-stranded, positive-sense RNA molecule, typical of coronaviruses, and is approximately 31,029 nucleotides in length, as determined from the complete genome sequence of the South Korean strain K37 [16]. This genomic size is consistent with that of other betacoronaviruses and positions CRCoV among the larger RNA viruses. The genome is organized in the canonical coronavirus order: 5′ to 3′, the leader sequence, the large replicase polyprotein genes (ORF1a and ORF1b), followed by the structural protein genes encoding the hemagglutinin-esterase (HE), spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins, interspersed with several accessory open reading frames (ORFs) [16, 19, 23]. The 3′ one-third of the genome, encompassing the structural and accessory protein genes, has been extensively characterized across multiple CRCoV isolates from diverse geographic regions, revealing both conservation and significant variability in the region between the S and E genes [2, 6, 19, 20].

Structural and Accessory Protein Genes

The spike (S) gene encodes a large, glycosylated transmembrane protein responsible for receptor binding and membrane fusion. Phylogenetic analyses of the S gene have demonstrated that CRCoV strains can be divided into at least five distinct clades, reflecting ongoing evolutionary diversification [6]. The S protein possesses a high degree of amino acid homology with BCoV and HCoV-OC43, but strain-specific mutations are consistently observed, particularly in the S1 subunit, which harbors the receptor-binding domain [1, 6]. The hemagglutinin-esterase (HE) gene is a hallmark of embecoviruses and encodes a glycoprotein with lectin and esterase activities that facilitate attachment to sialic acid receptors on host cells. For CRCoV, the HE protein is a critical determinant of tropism and virulence. Recent molecular docking analyses have identified specific amino acid substitutions, such as S158F and L161F in the HE lectin domain of emerging Chinese strains, which are predicted to enhance receptor-binding affinity, potentially increasing viral fitness and pathogenicity [1]. The membrane (M) gene, which encodes the most abundant structural protein, is relatively conserved and is frequently used as a target for molecular diagnostic assays due to its stability [3, 4]. The nucleocapsid (N) gene is also highly conserved within CRCoV subgroups and serves as an antigenic target for serological assays, including the development of recombinant proteins for diagnostic purposes [3, 15].

The Hypervariable Region Between S and E Genes

The genomic segment situated between the spike (S) and envelope (E) genes represents the most variable region of the CRCoV genome, both in terms of length and coding capacity [2, 16, 19, 20]. This region, often referred to as the nonstructural protein (nsp) region or the accessory gene cluster, encodes small, nonstructural proteins whose functions remain incompletely understood but are thought to be involved in host immune evasion and pathogenesis. Critically, this region displays substantial heterogeneity among CRCoV strains, and even between CRCoV and its close relative BCoV. The reference strain CRCoV-K37 encodes three small ORFs in this region, predicted to produce proteins of 4.9 kDa, 2.7 kDa, and 12.8 kDa [16]. In contrast, the Italian strain 240/05 encodes three proteins analogous to the BCoV products: a 4.9 kDa protein, a truncated 4.8 kDa protein, and a 12.7 kDa protein [20]. Remarkably, the British strain CRCoV-4182 possesses a unique mutation that fuses the equivalent of the 4.9 kDa and a truncated 4.8 kDa proteins into a single 8.8 kDa polypeptide [19]. This variation is not merely academic; it likely reflects adaptive evolution. For instance, Thai CRCoV strains have been shown to possess a nonsense mutation within this region, leading to a truncated putative nonstructural protein, a feature that distinguishes them from earlier strains [6]. Furthermore, the New Zealand CRCoV isolate was predicted to encode proteins of 5.9 kDa, 27 kDa, and 12.7 kDa in this interval, which differ from the coding capacities reported for viruses from other countries, underscoring the profound variability that can occur within a single host species [2]. These differences in the genes encoding these small, nonstructural proteins may be intimately associated with the emergence and adaptation of highly similar viruses in different hosts, including the cross-species transmission events that gave rise to BCoV and HCoV-OC43 [16]. Consecutive nucleotide deletions in non-coding regions between these ORFs have also been identified in both Chinese and Thai lineages, suggesting common evolutionary pressures or recombination events [1, 6].

Recombination and Evolutionary Dynamics

The genomic evolution of CRCoV is driven by a combination of point mutations and genetic recombination, a well-recognized mechanism for generating diversity among coronaviruses. Evidence of recombination between CRCoV and BCoV has been compellingly demonstrated. For example, the CRCoV-K37 strain was found to have originated from a genetic recombination event between a CRCoV-BJ232-like virus and a BCoV-like virus [14]. This finding highlights the potential for interspecies genetic exchange, which could facilitate the emergence of novel variants with altered host range or virulence. While some CRCoV populations, such as those circulating in Sweden and Thailand, appear to have evolved without significant recombination following a single introduction event [6, 12], analyses have identified Thai CRCoV strains as potential parent viruses for US strains, implying a role for recombination in the global dissemination of the virus [6]. Selective pressure analyses of the hypervariable S region indicate that CRCoV has predominantly undergone purifying selection during evolution, presumably eliminating most deleterious mutations while preserving key functional domains [6]. Evolutionary clock analyses estimate that CRCoV likely emerged around 1992 and was introduced into Thailand around 2004, sharing a common ancestor with Korean strains [6].

Diagnostic and Clinical Implications of Genomic Variability

The genomic organization and variability directly impact the development and performance of diagnostic assays. The conserved nature of the M and N genes makes them ideal targets for broad-spectrum detection by reverse transcription quantitative polymerase chain reaction (RT-qPCR) [3, 4]. Conversely, the hypervariable region between S and E, while less useful for universal detection, can serve as a marker for strain differentiation and epidemiological tracking. The high genetic similarity between CRCoV and BCoV presents challenges for serological diagnosis, as BCoV-based enzyme-linked immunosorbent assays (ELISA) cannot differentiate between BCoV and CRCoV infections [9]. This cross-reactivity necessitates the development of CRCoV-specific assays, such as the hemagglutination inhibition (HI) test, which shows a strong correlation with virus neutralization tests and is valuable for seroepidemiological surveys [9]. Furthermore, the genomic diversity of CRCoV underpins its capacity to cause significant respiratory disease, including pneumonia and acute respiratory distress syndrome (ARDS), as confirmed by experimental infections and clinical case reports [1, 5, 17]. The virus preferentially infects the upper respiratory tract, with a clear tropism for ciliated epithelial cells and goblet cells in the nares and trachea, leading to ciliary loss and inflammation [17, 21, 22]. This pathogenic potential, combined with its widespread seroprevalence, ranging from 35% to 53% in various global dog populations, solidifies CRCoV as a major component of the canine infectious respiratory disease complex (CIRDC) and a pathogen of significant veterinary and epidemiological concern [8, 13, 18].

Molecular Pathogenesis: Genetic Diversity, Mutations, and Receptor Interactions

Canine respiratory coronavirus (CRCoV) represents a paradigm of betacoronavirus evolution, exhibiting a dynamic genetic landscape that underpins its pathogenesis, host adaptation, and ongoing global dissemination. As a member of the Betacoronavirus 1 species, CRCoV shares a close phylogenetic relationship with bovine coronavirus (BCoV) and human coronavirus OC43 (HCoV-OC43), yet it has carved a distinct ecological niche within the canine respiratory tract [23, 28, 32]. The molecular mechanisms driving its pathogenesis are rooted in a complex interplay of genetic diversity, targeted mutations in key structural and nonstructural proteins, and sophisticated receptor interactions that govern cell tropism and immune evasion. Understanding these elements is critical for predicting viral emergence, informing vaccine design, and managing the global burden of canine infectious respiratory disease complex (CIRDC), a syndrome increasingly recognized by the World Organisation for Animal Health (WOAH) as a significant concern in shelter and kennel environments.

Genomic Architecture and Evolutionary Dynamics

The CRCoV genome, approximately 31,000 nucleotides in length, is organized similarly to other betacoronaviruses, with the canonical gene order 5′-replicase (ORF1ab)-hemagglutinin esterase (HE)-spike (S)-envelope (E)-membrane (M)-nucleocapsid (N)-3′ [16, 19]. However, the region situated between the S and E genes exhibits remarkable plasticity, encoding a variable number of small nonstructural proteins (nsps) that differ across strains and geographic lineages. This intergenic region serves as a hotspot for genetic variation, with implications for viral fitness and host interactions. For instance, the prototype CRCoV strain K37 encodes three nsps (4.9 kDa, 2.7 kDa, and 12.8 kDa), while the Italian strain 240/05 encodes three distinct products, including a truncated form of the 4.8 kDa protein [16, 20]. In contrast, the early isolate CRCoV-4182 possesses a unique fusion protein (8.8 kDa) resulting from a mutation that fuses the equivalent of the BCoV 4.9 kDa protein with a truncated 4.8 kDa counterpart [19]. This remarkable variability in coding capacity, also observed in a New Zealand strain that predicted proteins of 5.9 kDa, 27 kDa, and 12.7 kDa, suggests a dynamic evolutionary process that may influence species-specific adaptation and pathogenesis [3, __].

Phylogenetic analyses have consistently demonstrated that CRCoV strains cluster into distinct clades, often correlating with geographic origin and temporal emergence. The comprehensive characterization of five complete genomes from China in 2025 revealed a novel genetic branch, with the ORF1ab, HE, and S gene trees closely mirroring the full-genome topology, underscoring the pivotal role of these genes in CRCoV evolution [1]. Similarly, a study of 21 Thai CRCoV sequences spanning 2013–2022 demonstrated a clear phylogenetic shift over time, with group B strains (2021–2022) harboring signature nonsynonymous mutations in the S gene that were absent in earlier group A strains [6]. This ongoing evolutionary process is further supported by time-structured phylogeny, which estimated that CRCoV emerged globally around 1992 and was first introduced into Thailand in 2004, likely sharing a common ancestor with Korean strains [6]. The Swedish CRCoV population, however, tells a contrasting story of a single, relatively recent introduction around 2010, with subsequent circulation characterized by low genetic diversity and an absence of recombination [12]. These disparate evolutionary trajectories highlight the influence of local dog population dynamics, movement patterns, and selection pressures on viral diversification.

Key Mutations Driving Pathogenesis: Hemagglutinin Esterase and Spike Genes

The hemagglutinin esterase (HE) glycoprotein is a defining feature of betacoronavirus 1 members and plays a dual role in receptor binding and enzymatic destruction of sialic acid moieties. The HE lectin domain is responsible for initial attachment to sialic acids on the host cell surface, a critical first step in infection. Recent molecular docking analyses have identified two specific mutations, S158F and L161F, within the HE lectin domain of emerging Chinese CRCoV strains that are associated with improved docking scores, indicating a potential increase in receptor-binding affinity [1]. These mutations, located in a region critical for sialic acid recognition, may enhance viral attachment to canine respiratory epithelium, potentially increasing infectivity and transmissibility. The functional consequences of these substitutions warrant further investigation, as they may represent adaptive changes that facilitate viral spread in densely housed dog populations.

The spike (S) protein, the primary mediator of viral entry and a major determinant of host range and tissue tropism, is under continuous selective pressure. Selective pressure analysis of the hypervariable S region has revealed that CRCoV predominantly undergoes purifying (negative) selection, constraining amino acid changes to maintain critical structural and functional integrity [6]. Despite this constraint, the S gene exhibits notable diversity, with phylogenetic analysis dividing CRCoV strains into at least five distinct clades [6]. Nonsynonymous mutations have accumulated over time, with Thai group B strains displaying unique amino acid substitutions not found in earlier isolates, suggesting a directional evolution that may alter antigenicity or receptor interactions [6]. The S gene of CRCoV also shows evidence of recombination, a common mechanism among coronaviruses that can generate novel variants with altered pathogenic potential. One CRCoV strain (BJ232) from China was found to form a separate clade, and the CRCoV-K37 strain was derived from a recombination event between the BJ232 lineage and BCoV [14]. This capacity for interspecies recombination underscores the potential for CRCoV to acquire genetic material from related viruses, with unpredictable consequences for virulence and host range.

Receptor Interactions: Sialic Acids, HLA-1, and the Entry Pathway

For over a decade, it was assumed that CRCoV, like its close relatives BCoV and HCoV-OC43, utilized sialic acids as the primary receptor for viral entry. However, a landmark study employing a comprehensive panel of biochemical and cell-based assays fundamentally reframed our understanding of CRCoV receptor usage. While all three viruses bind to sialic acids on the cell surface, these moieties serve as attachment receptors rather than entry receptors for CRCoV and BCoV; only a clinical strain of HCoV-OC43 was capable of using sialic acids to mediate internalization [10]. Instead, CRCoV and BCoV appear to employ human leukocyte antigen class I (HLA-1) as the bona fide entry receptor [10]. This discovery has profound implications for understanding host range and species specificity. HLA-1 is a ubiquitously expressed molecule, but its utilization as a viral entry receptor may be influenced by species-specific polymorphisms and expression patterns in the canine respiratory tract. The identification of HLA-1 as an entry receptor also raises intriguing questions about the potential for CRCoV to interact with the host immune system at the molecular level, possibly modulating antigen presentation or triggering immunopathological cascades.

In addition to sialic acids and HLA-1, heparan sulfate proteoglycans have been identified as alternative attachment factors for CRCoV, although this interaction appears to be primarily a consequence of cell culture adaptation and may not play a significant role in natural infection in vivo [10]. The entry process itself is mediated through a caveolin-1-dependent endocytic pathway. Studies using chemical inhibitors and siRNA knockdown in HRT-18G cells have demonstrated that CRCoV hijacks caveolin-mediated endocytosis for internalization, co-localizing with caveolin-1 and exploiting the cellular machinery of lipid rafts [25]. This mechanism contrasts with the clathrin-mediated entry used by some other coronaviruses and may influence the intracellular trafficking, uncoating, and subsequent replication of CRCoV. The caveolin-dependent pathway is associated with non-degradative intracellular transport, potentially allowing the virus to evade lysosomal destruction and establish a productive infection.

Genetic Recombination and the Emergence of Novel Variants

Genetic recombination is a hallmark of coronavirus evolution and a primary driver of host range expansion and pathogenesis. Analysis of CRCoV genomes has provided compelling evidence for both inter- and intra-species recombination events. One Thai CRCoV strain (PP158_THA_2015) was identified as a potential parent virus for CRCoV strains circulating in the United States, suggesting a global dispersal network mediated by the movement of infected dogs [6]. More strikingly, the CRCoV-BJ232 lineage from China was shown to have recombined with BCoV to generate the CRCoV-K37 strain, demonstrating that cross-species recombination between canine and bovine coronaviruses can occur in nature [14]. This finding is particularly significant given that BCoV is a common pathogen of cattle worldwide, and the close contact between dogs and livestock in certain agricultural settings may provide a niche for such recombination events.

The emergence of the novel alphacoronavirus CCoV-HuPn-2018, isolated from a child with pneumonia in Malaysia, further underscores the zoonotic potential of coronaviruses originating from dogs [26, 30, 31]. Although CCoV-HuPn-2018 is an alphacoronavirus and genetically distinct from the betacoronavirus CRCoV, its spike protein exhibits an extensive recombinant history involving a feline coronavirus type II strain [29]. The spike 0-domain of this virus retains homology to enteric CCoV2b and transmissible gastroenteritis virus (TGEV) but has undergone relaxed selection pressure and unique amino acid substitutions in the sialic acid-binding region, potentially associated with a loss of enteric tropism and an adaptation to the human respiratory tract [29]. Cryo-electron microscopy structures of the CCoV-HuPn-2018 spike revealed that it binds canine, feline, and porcine aminopeptidase N (APN) as entry receptors, and a single N739 glycosylation site on human APN renders cells susceptible to spike-mediated entry, suggesting that host genetic polymorphisms could account for sporadic human infections [31]. While CRCoV itself has not been definitively linked to human disease, the precedent set by CCoV-HuPn-2018, coupled with the demonstrated ability of CRCoV to undergo recombination with BCoV and its use of the broadly expressed HLA-1 receptor, warrants continued surveillance at the animal-human interface. Serological surveys of occupationally exposed individuals have not detected antibodies against CRCoV, suggesting that current zoonotic transmission is absent or infrequent, but the potential for future adaptation should not be dismissed [27].

Implications for Pathogenesis and Epidemiology

The genetic diversity and receptor interactions of CRCoV directly shape its pathogenesis in the canine host. The primary tropism for the upper respiratory tract, with preferential infection of ciliated epithelial cells and goblet cells in the nasal mucosa and trachea, is consistent with the virus's reliance on sialic acid attachment and caveolin-mediated entry in these cell types [17, 21, 22]. The loss of tracheal cilia observed during experimental infection is a direct consequence of viral replication and contributes to mucociliary dysfunction, predisposing dogs to secondary bacterial infections and more severe respiratory disease [17, 21]. The suppression of pro-inflammatory cytokines (TNF-α, IL-6) and chemokines (IL-8) in infected tracheal epithelium further compromises the host's innate antiviral response, creating a window of vulnerability for pathogen co-infections [21]. This immunomodulatory strategy, combined with the high seroprevalence observed globally (ranging from 30–54% in various studies), positions CRCoV as a key initiator of CIRDC [8, 9, 13, 18].

The association between specific CRCoV genetic variants and disease severity is an area of active investigation. A recent case of acute respiratory distress syndrome (ARDS) in a dog with confirmed CRCoV infection, alongside the epidemiological association of CRCoV with more severe clinical outcomes in the Southeastern United States, suggests that strain-specific differences in virulence may exist [5, 7]. The mutations identified in the HE lectin domain (S158F, L161F) and the ongoing nonsynonymous changes in the S gene may alter the balance between attachment, entry, and immune recognition, potentially leading to variants with enhanced pathogenic potential [1, 6]. The detection of CRCoV in rectal swabs from clinically ill dogs using highly sensitive digital PCR assays indicates that the virus may also have an unrecognized enteric phase or be shed systemically in some cases, further complicating our understanding of its pathogenesis [24]. As global surveillance intensifies and genomic data accumulate, the molecular determinants of CRCoV virulence, transmission, and host adaptation will continue to be elucidated, providing a foundation for the development of targeted interventions and the modeling of future pandemic threats from this ubiquitous canine pathogen.

Clinical Manifestations and Pathological Findings in Canine Respiratory Disease

Spectrum of Clinical Disease Associated with CRCoV Infection

Canine respiratory coronavirus (CRCoV) is now recognized as a primary etiological agent within the canine infectious respiratory disease complex (CIRDC), yet its clinical presentation spans a remarkably broad spectrum, from subclinical infection to life-threatening acute respiratory distress syndrome (ARDS). The clinical manifestations are heavily influenced by host factors, particularly age and immune status, as well as viral strain virulence, environmental stressors, and the presence of concurrent pathogens [7, 17, 36]. Understanding this clinical heterogeneity is essential for accurate diagnosis, prognostication, and therapeutic intervention.

The most frequently observed clinical presentation of CRCoV infection is an acute, self-limiting upper respiratory tract illness that closely resembles classical kennel cough. Affected dogs typically present with a persistent, dry, hacking cough that may be paroxysmal and often culminates in gagging or retching, accompanied by serous to mucoid nasal discharge and sneezing [17, 23, 33]. These signs generally emerge following an incubation period of approximately 3–7 days post-exposure, with viral shedding from the oropharynx detectable for up to 10 days after infection [17]. Importantly, systemic signs such as pyrexia, lethargy, and anorexia are typically absent or mild in uncomplicated cases, which has historically led to the perception of CRCoV as a relatively benign pathogen [11, 23]. However, this characterization belies the virus’s capacity to cause significant morbidity under specific conditions.

In kenneled or shelter populations, where dogs are subjected to the physiological and immunological stress of crowding, transport, and novel environment exposure, the clinical picture can be considerably more severe. Epidemiological studies have consistently demonstrated that CRCoV seroprevalence and clinical disease incidence are highest in multi-dog environments, with seropositivity rates reaching 35–54% in breeding kennels and shelters globally [8, 13, 18]. In these settings, the virus contributes to outbreaks of CIRDC characterized by more pronounced coughing, mucopurulent nasal discharge, and occasional progression to bronchopneumonia [28, 36]. The severity of disease in such environments is likely multifactorial, reflecting higher infectious doses, co-circulation of other pathogens, and stress-induced immunosuppression.

A critical observation from experimental infection studies is that CRCoV alone, in the absence of co-pathogens, can induce clinically apparent respiratory disease. Mitchell et al. (2012) demonstrated that experimental inoculation of dogs with five geographically distinct CRCoV isolates consistently produced clinical signs consistent with natural infection, including coughing, nasal discharge, and malaise [17]. This work fulfilled Koch’s postulates and definitively established CRCoV as a primary respiratory pathogen, not merely an opportunistic or incidental agent. The clinical signs observed were mild to moderate in severity, with peak manifestation occurring between days 4 and 8 post-infection, correlating with the period of maximal viral shedding [17].

Severe Manifestations: Pneumonia and Acute Respiratory Distress Syndrome

While the majority of CRCoV infections follow a benign course, a growing body of evidence indicates that the virus can be associated with severe, even fatal, lower respiratory tract disease. Experimental infection with a Chinese CRCoV strain (106 TCID50/mL) confirmed the virus’s ability to induce pneumonia, characterized by pulmonary consolidation and histopathological evidence of interstitial inflammation [1]. This finding aligns with earlier work demonstrating CRCoV detection in lung parenchyma and bronchial lymph nodes of naturally infected dogs, confirming that the virus can extend beyond its primary upper respiratory tract tropism [22].

The most dramatic illustration of CRCoV’s pathogenic potential comes from a recent case report describing ARDS in a previously healthy 1.5-year-old Rottweiler [5]. This dog presented with acute respiratory distress following a prodromal phase of productive cough, lethargy, and anorexia that occurred during a boarding stay. Thoracic radiography revealed severe cranioventral lung lobe consolidation, and the dog rapidly deteriorated despite aggressive supportive care, including positive pressure ventilation. Necropsy confirmed diffuse alveolar damage consistent with ARDS, and metagenomic analysis of lung tissue identified CRCoV as the sole infectious agent, with negative bacterial cultures [5]. This case is particularly instructive for several reasons. First, it demonstrates that CRCoV can serve as a primary trigger for the catastrophic inflammatory cascade underlying ARDS, a condition previously unassociated with this virus. Second, the authors proposed that direct viral pulmonary damage, combined with virus-induced impairment of mucociliary clearance and subsequent aspiration, likely contributed to the pathogenesis [5]. Third, the case underscores the potential for CRCoV to cause severe disease in young, immunocompetent animals, challenging the prevailing view of the virus as exclusively mild.

The mechanisms by which CRCoV transitions from a mild upper respiratory pathogen to a cause of severe pneumonia and ARDS are incompletely understood but likely involve a combination of viral cytopathology, host inflammatory dysregulation, and secondary insults. The virus’s tropism for ciliated epithelial cells and goblet cells in the trachea and bronchi [17, 21] directly compromises the mucociliary escalator, predisposing to aspiration of oropharyngeal contents and secondary bacterial infection. Furthermore, as discussed below, CRCoV infection suppresses key pro-inflammatory cytokine responses, which may paradoxically impair pathogen clearance while simultaneously permitting unchecked viral replication and tissue damage.

Co-infections and Clinical Severity

CRCoV rarely circulates in isolation, and co-infections with other CIRDC pathogens are the rule rather than the exception. Epidemiological studies from multiple continents have documented that CRCoV is frequently detected alongside canine parainfluenza virus (CPIV), canine adenovirus type 2 (CAV-2), Mycoplasma cynos, Bordetella bronchiseptica, and canine influenza virus (CIV) [7, 35-38]. The clinical significance of these co-infections cannot be overstated. Statistical modeling has demonstrated that the presence of CRCoV, either alone or in co-infection, is significantly associated with a worse prognosis and more severe clinical disease [7]. In particular, co-detection of CRCoV with CIV has been identified as a particularly virulent combination, with synergistic worsening of respiratory signs and prolonged disease duration [34, 38].

The biological basis for this synergy is multifaceted. CRCoV-induced damage to the respiratory epithelium and suppression of innate immune responses [21] likely creates a permissive environment for secondary pathogens to establish infection and cause more extensive tissue damage. Conversely, concurrent infection with other viruses may enhance CRCoV replication through immune modulation or by providing additional cellular targets. The high prevalence of co-infections in clinical cases, ranging from 78.9% to 81.2% in some studies [38], highlights the importance of comprehensive diagnostic testing in dogs presenting with respiratory disease, as targeted therapy against a single agent may be insufficient.

Age-Related Susceptibility and Clinical Outcome

Age is one of the most consistent predictors of CRCoV infection risk and clinical outcome. Multiple serosurveys have demonstrated that seroprevalence increases with age, with dogs under one year of age showing significantly lower antibody titers compared to adults aged 3–5 years [9, 13, 18]. However, this age-related increase in seropositivity does not translate to protection from disease; rather, younger dogs appear more susceptible to clinical illness. In the Southeastern United States, CRCoV-positive cases were significantly more likely to occur in younger dogs [7], and in Thailand, clinical severity was notably related to age, with younger animals experiencing more severe disease [38]. This paradox, higher seroprevalence but lower clinical disease in older dogs, suggests that repeated exposure throughout life may confer partial immunity that mitigates disease severity without preventing reinfection. This pattern is reminiscent of other respiratory coronaviruses, including human coronavirus OC43, and has important implications for vaccine development and management strategies in kennel environments.

Pathological Findings: Gross and Histopathological Lesions

The pathological hallmarks of CRCoV infection reflect the virus’s primary tropism for the ciliated epithelium of the upper respiratory tract, with variable involvement of the lower airways depending on disease severity. Gross pathological findings in uncomplicated cases are often subtle, limited to hyperemia and edema of the nasal mucosa and tracheal mucosa, with increased mucus production [17]. However, in more severe cases, particularly those progressing to pneumonia, gross lesions become more pronounced. Pulmonary consolidation, most frequently affecting the cranioventral lung lobes, has been described in both experimental and natural infections [1, 5]. The consolidated lung tissue is typically firm, dark red to purple, and fails to collapse upon opening the thoracic cavity, consistent with interstitial pneumonia.

Histopathological examination reveals the most characteristic and diagnostically useful lesions. The seminal experimental study by Mitchell et al. (2012) provided a comprehensive description of the histopathological changes associated with CRCoV infection [17]. In the nasal mucosa and trachea, the most striking finding is loss and damage to cilia on epithelial cells, accompanied by varying degrees of epithelial cell degeneration, necrosis, and sloughing. This ciliary damage is not merely an incidental finding; it represents a critical pathogenic mechanism. The mucociliary escalator is the first line of defense against inhaled pathogens and particulate matter, and its disruption by CRCoV predisposes to secondary bacterial colonization and aspiration pneumonia [17, 21]. The loss of ciliary function has been quantitatively confirmed in air-interface tracheal culture systems, where CRCoV infection significantly reduced ciliary beat frequency and coordination [21].

Inflammation in the tracheal mucosa is typically mild to moderate, characterized by infiltration of mononuclear cells, primarily lymphocytes and plasma cells, with fewer neutrophils. This inflammatory infiltrate is most prominent in the lamina propria and around submucosal glands [17]. In the lower respiratory tract, histopathological changes are more variable. In experimentally infected dogs, pulmonary lesions range from mild peribronchiolar lymphocytic cuffing to more severe interstitial pneumonia with thickening of alveolar septa due to mononuclear cell infiltration and type II pneumocyte hyperplasia [1]. In the ARDS case described by Fisher et al. (2026), the histopathological picture was dominated by diffuse alveolar damage, including hyaline membrane formation, alveolar edema, and extensive type II pneumocyte proliferation, consistent with the exudative and proliferative phases of ARDS [5].

Immunopathogenesis and Cytokine Dysregulation

A particularly intriguing aspect of CRCoV pathogenesis is the virus’s ability to modulate the host innate immune response. Using canine air-interface tracheal epithelial cultures, a system that faithfully recapitulates the in vivo respiratory epithelium, Priestnall et al. (2008) demonstrated that CRCoV infection significantly reduces mRNA levels of key pro-inflammatory cytokines and chemokines [21]. Specifically, tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-8 (IL-8) were all downregulated during the 72-hour period following inoculation. This suppression of the innate immune response is counterintuitive for a pathogen that causes clinical disease, as one might expect an exuberant inflammatory response to be responsible for tissue damage.

The mechanism by which CRCoV achieves this cytokine suppression remains unknown, but it likely represents a viral immune evasion strategy. By dampening the early pro-inflammatory response, CRCoV may delay or attenuate the recruitment of immune effector cells to the site of infection, allowing the virus to replicate to higher titers before the host mounts an effective response. This strategy is reminiscent of other group 2 coronaviruses, including SARS-CoV and SARS-CoV-2, which have evolved multiple mechanisms to antagonize interferon signaling and suppress innate immunity. The clinical consequence of this immune modulation is that during periods of physiological or immunological stress, such as entry into a kennel, transport, or concurrent infection, the suppression of key antiviral defenses could predispose dogs to more severe disease and secondary pathogen invasion [21].

Furthermore, the downregulation of IL-8, a potent neutrophil chemoattractant, may explain the relative paucity of neutrophilic inflammation observed in uncomplicated CRCoV infections. This contrasts with bacterial respiratory infections, where neutrophilic infiltration is a hallmark. The lymphoplasmacytic nature of the inflammatory infiltrate in CRCoV infection suggests a predominantly adaptive immune response, which may be slower to develop but ultimately more effective at viral clearance.

Tissue Tropism and Viral Distribution

The tissue distribution of CRCoV within the respiratory tract has been systematically characterized using both conventional and quantitative PCR techniques. Mitchell et al. (2009) demonstrated that CRCoV is detected most frequently and at highest copy numbers in the nasal mucosa, nasal tonsil, and trachea, confirming the upper respiratory tract as the primary site of infection [22]. Viral RNA was also detected in lung tissue and bronchial lymph nodes, albeit at lower levels, indicating that the virus can spread to the lower respiratory tract but does so less efficiently. Importantly, CRCoV was rarely detected in enteric tissues; only one mesenteric lymph node sample and two colon samples were positive, and these were detected only by nested PCR, suggesting very low viral loads [22]. This tissue tropism distinguishes CRCoV sharply from canine enteric coronavirus (CCoV), which primarily infects the gastrointestinal tract, and underscores the respiratory specialization of this betacoronavirus.

The cellular targets of CRCoV within the respiratory epithelium have been identified using immunohistochemistry. In both naturally infected dogs and experimentally infected tracheal cultures, CRCoV antigen is localized predominantly to ciliated epithelial cells and goblet cells [17, 21]. This cellular tropism explains the profound effect of the virus on ciliary function and mucus production, as these are the very cells responsible for maintaining the mucociliary escalator. The infection of goblet cells may also contribute to the increased mucus production observed clinically, as these cells are the primary source of respiratory tract mucus.

Temporal Dynamics of Infection and Seroconversion

The temporal course of CRCoV infection has been well characterized in experimental models. Following intranasal inoculation, viral shedding from the oropharynx is detectable by RT-PCR as early as day 2 post-infection, peaks between days 4 and 8, and becomes undetectable by day 10–14 [17]. This shedding pattern correlates closely with the appearance and resolution of clinical signs. Importantly, rectal shedding is minimal or absent, confirming that fecal-oral transmission is not a significant route for CRCoV, unlike enteric coronaviruses [17]. This has important implications for biosecurity measures in kennel settings, as respiratory droplet and fomite transmission are the primary routes of spread.

Seroconversion occurs reliably by day 14 post-infection, with neutralizing antibodies detectable against both homologous and heterologous CRCoV strains [17]. This antigenic homogeneity among CRCoV strains from different continents is a notable feature and suggests that a single vaccine strain could potentially provide broad protection. The presence of pre-existing antibodies to CRCoV on entry into a kennel environment has been shown to decrease the risk of developing respiratory disease, indicating that natural infection confers at least partial protective immunity [23]. However, the duration of this immunity and its efficacy against heterologous challenge remain poorly defined.

Breed and Environmental Risk Factors

While CRCoV can infect dogs of any breed, certain environmental and management factors significantly influence the risk of infection and disease severity. Dogs housed in kennels, shelters, and boarding facilities are at substantially higher risk, reflecting the high density of animals, shared airspace, and stress-induced immunosuppression [8, 28, 36]. Seroprevalence rates in such environments consistently exceed 50%, compared to 30–40% in pet dogs [8, 18]. Interestingly, daily cleaning and disinfection protocols in kennels have shown little effect on infection spread, suggesting that the virus is highly contagious and can persist in the environment despite routine hygiene measures [8].

Geographic and seasonal variations in CRCoV prevalence have been observed, though patterns are not consistent across studies. In the Southeastern United States, CRCoV detection was significantly higher during warmer weather [7], while in New Zealand, seroprevalence was highest in June (winter) and lowest in July–August [13]. These discrepancies likely reflect differences in climate, dog management practices, and circulating viral strains. Urban environments have been associated with higher seroprevalence in some studies, possibly reflecting greater dog density and more frequent contact between animals [7].

Implications for Clinical Management and Diagnosis

The clinical manifestations and pathological findings described above have direct implications for the diagnosis and management of CRCoV infection. The similarity of clinical signs to those caused by other CIRDC pathogens, including CPIV, CAV-2

Epidemiology of CRCoV: Prevalence, Transmission, and Role in Canine Infectious Respiratory Disease Complex

Global Seroprevalence and Geographic Distribution

Since its initial identification in 2003 from dogs with canine infectious respiratory disease (CIRD) in a large rehoming kennel in the United Kingdom [23], canine respiratory coronavirus (CRCoV) has emerged as a globally distributed pathogen with a remarkably high seroprevalence across diverse canine populations. The virus, a betacoronavirus closely related to bovine coronavirus (BCoV) and human coronavirus OC43 [10, 32], has been documented on every continent where surveillance has been conducted, establishing itself as a ubiquitous component of the canine respiratory pathogen landscape.

The earliest comprehensive serological surveys revealed that CRCoV had already achieved widespread circulation prior to its formal discovery. A landmark study examining serum samples from North America and the United Kingdom demonstrated that 54.7% (547/1000) of North American dogs and 36.0% (297/824) of United Kingdom dogs were seropositive for CRCoV [18]. This foundational work established that CRCoV was not a novel, emerging pathogen but rather a long-standing, endemic infection that had simply evaded detection. Subsequent investigations have confirmed similarly high seroprevalence rates across the globe. In New Zealand, a large-scale survey of 1,015 canine serum samples found an overall seroprevalence of 53.0%, with 53.4% positivity in the North Island and 49% in the South Island [13]. Notably, seroprevalence in New Zealand dogs aged three years or older was significantly higher than in younger dogs, and dogs with reported respiratory signs exhibited a seroprevalence of 67.9% compared to 52.6% in asymptomatic animals [13]. In Croatia, the first serological investigation of CRCoV reported 35.03% seropositivity in breeding kennels and 43% in pet dogs, with no statistically significant difference between these populations [8]. A study from South Korea utilizing a hemagglutination inhibition (HI) test, which demonstrated strong correlation with virus neutralization (VN) testing (R = 0.83, p < 0.001), revealed that 52.2% (95% CI: 47.2%–57.1%) of Korean dogs were seropositive, with positivity rates increasing from 43.9% in dogs under one year of age to 66.7% in dogs aged three to five years (odds ratio [OR], 2.54; 95% CI, 1.43–4.59) [9]. In Italy, serological investigations using an ELISA based on the closely related BCoV antigen demonstrated an overall CRCoV seroprevalence of 32.06% among 216 dog sera collected between 2005 and 2006 [40]. The Southeastern United States has also been characterized, with a retrospective seroprevalence of 23.7% estimated from 540 serum samples, although this lower figure likely reflects differences in sampling methodology and population demographics compared to kennel-based studies [7].

These data collectively indicate that CRCoV seroprevalence typically ranges from 30% to 55% in general canine populations, with higher rates observed in kenneled or shelter environments where transmission dynamics are amplified. The variation across studies reflects differences in sampling strategies, diagnostic methodologies, and population risk profiles rather than true geographic heterogeneity in virus distribution.

Prevalence in Clinical Cases and Asymptomatic Carriers

Molecular detection of CRCoV RNA in respiratory specimens provides a more direct measure of active infection, though prevalence estimates vary considerably depending on the clinical status of the population sampled, the diagnostic assay employed, and the type of specimen collected. In a study of 189 nasal swabs from dogs in the Southeastern United States, 14% of dogs were PCR-positive for CRCoV, and notably, all positive dogs were diagnosed with CIRD, with no CRCoV detected in asymptomatic dogs [7]. This association between CRCoV detection and clinical disease has been corroborated by multiple investigations. In Sweden, screening of 88 privately-owned dogs with characteristic signs of CIRD yielded a CRCoV detection rate of 14.7% (95% CI: 8.4%–23.7%) [12]. In Austria, CRCoV was the most commonly detected virus in upper airway samples from dogs with respiratory infections, found in 7.5% of cases, with serological evidence of seroconversion in 50% of acutely diseased dogs [45]. A large-scale European surveillance study, the most extensive of its kind, provided substantial evidence linking CRCoV to disease in kenneled dogs and, for the first time, demonstrated circulation of the virus in pet dogs and other canine cohorts [46].

However, CRCoV is also detected in apparently healthy dogs, underscoring the complexity of its role in CIRD. In a study of 503 asymptomatic dogs presented at US animal shelters, 47.7% were PCR-positive for at least one CIRD pathogen, though CRCoV was not among the most frequently detected agents in this particular survey [49]. In New Zealand, CRCoV RNA was detected in only 1 of 56 (2%) CIRD-affected dogs and was not detected in any of 60 healthy dogs, despite a seroprevalence of approximately 50% in the same population [43, 44]. This discrepancy between molecular detection and serological evidence suggests that CRCoV infection may be acute and self-limiting, with viral RNA clearance occurring relatively rapidly, while antibodies persist for extended periods. Alternatively, the virus may replicate to low levels that fall below the detection threshold of conventional RT-qPCR assays. Indeed, the development of highly sensitive nanoplate-based reverse transcription digital PCR (RT-dPCR) has revealed that CRCoV detection rates are substantially higher than previously appreciated, with the RT-dPCR assay demonstrating 100-fold greater sensitivity than probe-based RT-qPCR and detecting CRCoV in 53.7% of rectal swabs compared to only 22.22% by RT-qPCR [24]. This finding has profound implications for understanding the true prevalence of CRCoV, as many infections may be missed by conventional molecular diagnostics.

In China, a comprehensive investigation of 1,688 clinical samples from pet hospitals in Guangxi province during 2022–2024 using a quadruplex RT-qPCR assay found a CRCoV positivity rate of 8.65% (146/1688), comparable to the 8.59% positivity rate for canine enteric coronavirus (CCoV) in the same population [3]. A broader Chinese survey spanning 2018–2024 and encompassing 2,492 samples from 22 provinces detected CRCoV among a panel of ten canine viral pathogens, though CPV-2 (30.6%) and CCoV were more prevalent overall [48]. In Thailand, CRCoV was detected in dogs during two distinct time periods (2013–2015 and 2021–2022), with genomic characterization revealing ongoing evolutionary processes and the emergence of signature nonsynonymous mutations in the spike gene over time [6].

Age, Seasonal, and Environmental Risk Factors

The epidemiology of CRCoV is shaped by a complex interplay of host, environmental, and temporal factors. Age is one of the most consistently identified risk factors for CRCoV seropositivity and infection. Multiple studies have demonstrated that seroprevalence increases with age, with the lowest rates observed in puppies and young dogs and the highest rates in adult dogs aged three to five years [7, 9, 13]. In the Southeastern United States, CRCoV PCR positivity was significantly higher in younger dogs, while seroprevalence showed no statistical association with age, suggesting that active infection occurs predominantly in younger animals but that antibody persistence leads to cumulative seropositivity in older cohorts [7]. In Korea, dogs aged three to five years had 2.54 times higher odds of seropositivity compared to dogs under one year of age [9]. This age distribution pattern is consistent with endemic respiratory pathogens where initial infection occurs early in life, followed by seroconversion and long-term antibody maintenance.

Seasonal patterns of CRCoV infection have been observed but are not universally consistent across geographic regions. In the Southeastern United States, CRCoV detection was significantly associated with warmer weather [7]. In New Zealand, the lowest seroprevalence was observed in July (28.5%) and August (32%), while the highest was in June (74%), though the authors noted that factors other than external temperatures may be more important in the epidemiology of CRCoV in that region [13]. In the United Kingdom, antibody responses to CRCoV in kenneled dog populations indicated a seasonal occurrence that coincided with outbreaks of respiratory disease [41]. These seasonal variations may reflect environmental factors that influence virus survival and transmission, such as humidity and temperature, as well as behavioral factors that affect dog aggregation and contact rates.

Environmental and management factors are critical determinants of CRCoV transmission dynamics. The virus is highly contagious and achieves its highest prevalence in rehoming shelters, breeding kennels, and other multi-dog establishments where dogs are closely housed and turnover is high [11, 28, 36]. In Croatia, daily cleaning and disinfection showed little effect on infection spread, highlighting the challenges of controlling CRCoV in kennel environments [8]. Interestingly, mixing of dogs during hunting, training, and dog shows was not associated with higher seroprevalence in breeding colonies, suggesting that sustained close contact in confined spaces may be more important for transmission than transient interactions [8]. Urban counties in the Southeastern United States had significantly higher CRCoV seroprevalence compared to rural areas, potentially reflecting higher dog population densities and increased opportunities for transmission [7].

Transmission Dynamics and Shedding Patterns

CRCoV is primarily transmitted through direct contact with respiratory secretions and aerosols, consistent with its tropism for the upper respiratory tract [17, 22]. Experimental infection studies have provided critical insights into the transmission dynamics of CRCoV. Following experimental inoculation, viral shedding is readily detected from the oropharynx for up to 10 days post-infection, with little or no evidence of rectal shedding [17]. This pattern contrasts sharply with enteric canine coronaviruses, which are primarily shed in feces and cause gastrointestinal disease. The preferential shedding from the respiratory tract has important implications for diagnostic sampling strategies, with nasal swabs and oropharyngeal swabs representing the optimal specimens for molecular detection [22, 45].

The tissue tropism of CRCoV has been systematically characterized using quantitative real-time PCR. In dogs from a rehoming center with endemic respiratory disease, CRCoV was detected most frequently in the nasal mucosa, nasal tonsil, and trachea, with lower detection rates in the lung and bronchial lymph node [22]. Enteric tissues were rarely positive, with only one mesenteric lymph node sample and two colon samples yielding positive results by nested PCR [22]. This clear tropism for respiratory tissues was confirmed by experimental infection, where successful re-isolation of CRCoV from a wide range of respiratory and mucosa-associated lymphoid tissues, as well as lung lavage fluids, fulfilled the final requirement for Koch's postulates [17]. The virus employs caveolin-1-mediated endocytosis for internalization into host cells, a pathway that may influence its cellular tropism and pathogenesis [25].

The role of fomites and environmental contamination in CRCoV transmission is less well understood but is likely significant given the stability of coronaviruses on surfaces. The virus is susceptible to household disinfectants, and cleaning of contaminated areas and bedding can help limit disease spread [39]. However, the high prevalence of CRCoV in kennel environments despite routine cleaning suggests that direct dog-to-dog transmission via respiratory droplets is the primary route of spread [8].

Role in Canine Infectious Respiratory Disease Complex (CIRDC)

CRCoV is now recognized as a major component of the canine infectious respiratory disease complex (CIRDC), a multifactorial syndrome involving sequential or synergistic interactions between viral and bacterial pathogens [28, 36, 50]. The virus was first identified during an investigation of CIRD outbreaks in a large rehoming kennel, where it was detected by RT-PCR in 32 of 119 (26.9%) tracheal samples and 20 of 119 (16.8%) lung samples, with the highest prevalence observed in dogs with mild clinical symptoms [23]. Importantly, serological analysis showed that the presence of antibodies against CRCoV on the day of entry into the kennel decreased the risk of developing respiratory disease, providing early evidence for the protective role of humoral immunity [23].

The pathogenic potential of CRCoV has been definitively established through experimental infection studies. Following experimental inoculation with five geographically unrelated CRCoV isolates, all gave rise to clinical signs of respiratory disease consistent with natural infection, including coughing, sneezing, and nasal discharge [17]. The presence of CRCoV was associated with marked histopathological changes in the nares and trachea, including loss and damage to tracheal cilia accompanied by inflammation [17]. These ciliary changes are particularly significant because they compromise the mucociliary escalator, a critical innate immune defense mechanism that clears pathogens and debris from the respiratory tract. CRCoV has been shown to reduce mRNA levels of pro-inflammatory cytokines TNF-α and IL-6 and the chemokine IL-8 in canine tracheal epithelium, suggesting that the virus may suppress key antiviral strategies and predispose dogs to secondary infections [21]. This immunosuppressive effect is likely a major mechanism by which CRCoV contributes to CIRD, as the damage to the respiratory epithelium and suppression of innate immunity create opportunities for other pathogens to establish infection.

The clinical significance of CRCoV in CIRD is underscored by its association with more severe disease outcomes. In the Southeastern United States, the presence of CRCoV, alone or in coinfection with other CIRD pathogens, was statistically associated with a worse prognosis [7]. A landmark case report described acute respiratory distress syndrome (ARDS) in a previously healthy 1.5-year-old Rottweiler with confirmed CRCoV infection, demonstrating that this virus, primarily associated with mild upper respiratory signs, can under certain circumstances contribute to life-threatening pulmonary pathology [5]. Necropsy revealed diffuse alveolar damage consistent with ARDS, and metagenomic analysis confirmed the presence of CRCoV in lung tissue [5]. This case highlights the potential for CRCoV to cause severe disease, particularly when combined with other factors such as aspiration or secondary bacterial infection.

Coinfections are a hallmark of CIRD, and CRCoV is frequently detected alongside other respiratory pathogens. In Thailand, co-detection of canine influenza virus (CIV) and CRCoV represented the highest proportion of coinfections and was most often found with other CIRD viruses [38]. In a study of 459 cases from a veterinary diagnostic laboratory in Georgia, USA, CRCoV was detected in 7% of cases, with viral agents overall detected in 34% of cases and bacterial agents in 58% [35]. A comprehensive multiplex PCR panel study of 76 clinical specimens from CIRD-suspected dogs identified CRCoV in 19.7% of samples, making it the third most frequently detected pathogen after Mycoplasma canis (30.3%) and Mycoplasma cynos (25.0%) [42]. In Europe, CRCoV and canine pneumovirus (CnPnV) have been identified as important new elements in the etiology of CIRD, spreading particularly well in multi-dog establishments [36]. The most severe forms of respiratory disease have been observed in dogs infected with M. cynos alone or in combination with either CRCoV or M. canis, emphasizing the synergistic interactions between viral and bacterial pathogens in CIRD pathogenesis [47].

Evolutionary Epidemiology and Molecular Epidemiology

The global molecular epidemiology of CRCoV reveals a complex evolutionary history characterized by multiple introductions, genetic recombination, and ongoing adaptive evolution. Phylogenetic analyses have consistently demonstrated that CRCoV strains cluster within the Betacoronavirus 1 species, closely related to BCoV and HCoV-OC43, but form distinct genetic lineages that reflect geographic and temporal patterns of diversification [1, 6, 7, 12, 14].

Time-structured phylogenetic analyses have provided estimates of the evolutionary timescale of CRCoV. Evolutionary analysis suggests that CRCoV emerged around 1992 and was first introduced into Thailand in 2004, sharing a common ancestor with Korean CRCoV strains [6]. In Sweden, a single introduction of CRCoV into the dog population occurred around 2010, with subsequent spread and endemic establishment [12]. Swedish CRCoV isolates were highly similar despite being detected in dogs living in geographically distant locations and sampled across three years (2013–2015), consistent with a single introduction and low levels of subsequent diversification [12]. Unlike CRCoVs from other regions, there was no evidence of recombination in Swedish CRCoV viruses, further supporting a single introduction event [12].

In contrast, CRCoV strains from Asia and North America exhibit greater genetic diversity. Thai CRCoV strains obtained during two time periods (2013–2015 and 2021–2022) showed distinct genomic characteristics and formed a unique phylogenetic cluster, with group B strains (2021–2022) possessing signature nonsynonymous mutations in the spike gene that were not identified in group A strains (2013–2015), suggesting ongoing evolutionary processes [6]. Full-length genome characterization revealed that all Thai CRCoVs possessed a nonsense mutation within the nonstructural gene located between the spike and envelope genes, leading to a truncated putative nonstructural protein [6]. This region between the spike and E genes is the most variable part of the CRCoV genome and has been used for phylogenetic analysis of different strains [19]. The coding capacity of this region varies among CRCoV strains, with some encoding three nonstructural proteins (4.9 kDa, 2.7 kDa, and 12.8 kDa), while others encode different combinations, and these differences may be associated with the emergence of highly similar viruses in different hosts [16, 20].

Evidence for genetic recombination in CRCoV evolution has been documented. One study identified a CRCoV strain (K37) that was derived from genetic recombination between a CRCoV-BJ232 lineage strain and BCoV [14]. Additionally, a Thai CRCoV strain (PP158_THA_2015) was identified as a potential parent virus for CRCoV strains found in the United States, suggesting international dissemination of viral lineages [6]. In China, five complete CRCoV genomes obtained from clinical samples formed a distinct genetic branch, with evolutionary trees for ORF1ab, HE, and S genes closely mirroring the full genome tree, indicating key roles for these genes in CRCoV evolution [1]. Multiple unique amino acid mutations were identified in the ORF1ab, HE, S, M, and N proteins, and molecular docking analysis suggested that mutations S158F and L161F in the HE lectin domain are associated with improved docking scores, potentially indicating increased receptor-binding affinity [1].

The selective pressures acting on CRCoV have been investigated through analysis of the hyper

Advances in Molecular Diagnostics: Development and Validation of RT-dPCR Assays

The accurate and sensitive detection of canine respiratory coronavirus (CRCoV) is paramount for understanding its epidemiology, pathogenesis, and role within the canine infectious respiratory disease complex (CIRDC). While traditional molecular methods such as reverse transcription quantitative polymerase chain reaction (RT-qPCR) have been foundational in CRCoV diagnostics, they are inherently limited by their reliance on standard curves for quantification and their susceptibility to inhibition, which can compromise sensitivity, particularly in samples with low viral loads. The recent development and rigorous validation of reverse transcription digital polymerase chain reaction (RT-dPCR) technologies represent a paradigm shift, offering absolute quantification without the need for external calibrators and exhibiting a heightened resilience to PCR inhibitors [24]. This section provides an exhaustive analysis of these advanced molecular diagnostics, focusing on the development, validation, and comparative advantages of RT-dPCR assays for CRCoV detection, while also contextualizing them within the broader landscape of multiplex and next-generation diagnostic platforms.

The Paradigm Shift from Relative to Absolute Quantification: The RT-dPCR Advantage

The fundamental principle of digital PCR distinguishes it fundamentally from real-time PCR. Instead of measuring amplification in a bulk reaction via fluorescence intensity, dPCR partitions the sample into thousands to millions of individual nanoliter-sized reactions. Following endpoint amplification, the fraction of positive partitions (containing at least one target molecule) is counted, and the absolute number of target copies in the original sample is calculated using Poisson statistics. This absolute quantification eliminates the variability and bias associated with standard curves, making RT-dPCR a “gold standard” for precise nucleic acid measurement.

Building on this principle, Poonsin et al. [24] developed and validated a groundbreaking nanoplate-based RT-dPCR assay targeting the spike (S) gene of CRCoV. The assay’s design was meticulously optimized, focusing on the S gene due to its role in viral attachment and its potential for variability, which could impact diagnostic target selection. The validation process was exhaustive, demonstrating exceptional analytical performance. The assay exhibited a limit of detection (LOD) of 1.83 copies/µL, which is a staggering 100-fold more sensitive than a comparator probe-based RT-qPCR assay [24]. This enhanced sensitivity is not merely a technical achievement; it carries profound epidemiological and clinical implications. It enables the detection of CRCoV in samples with extremely low viral loads, such as in subclinical infections, early stages of disease, or in sample types where viral shedding is minimal or intermittent. Critically, the RT-dPCR assay demonstrated no cross-reactivity with a panel of other common CIRDC-associated pathogens, including canine parainfluenza virus, canine adenovirus type 2, canine distemper virus, and canine influenza virus, as well as other coronaviruses like canine enteric coronavirus, confirming its exceptional specificity for CRCoV [24].

Clinical Validation and Sample Type Stratification

The true value of a diagnostic tool is established through its performance on clinical specimens. Poonsin et al. [24] deployed their RT-dPCR assay on 162 clinical swab samples, nasal (NS), oropharyngeal (OS), and rectal (RS), from both healthy dogs and those exhibiting respiratory distress. The results were striking and provided critical insights into CRCoV epidemiology. The overall positivity rate for CRCoV was significantly higher via RT-dPCR compared to RT-qPCR. The most dramatic difference was observed in rectal swabs, where RT-dPCR detected CRCoV in 53.7% of samples, versus only 22.2% by RT-qPCR [24]. This finding is of immense biological significance. It challenges the long-held assumption that CRCoV tropism is strictly limited to the respiratory tract [17, 22]. The detection of viral RNA in rectal samples, particularly at levels detectable only by the ultra-sensitive RT-dPCR, suggests that CRCoV may undergo enteric shedding, potentially implicating a fecal-oral route of transmission that has been largely overlooked. This discovery has profound implications for biosecurity protocols in kennels and shelters, and for understanding the full transmission dynamics of the virus.

The robust performance of RT-dPCR across all three sample types (NS, OS, RS) and its superior sensitivity underlines its value for comprehensive surveillance. For clinical diagnostics, this means that RT-dPCR can serve as a definitive, highly sensitive confirmatory test, especially for samples that yield equivocal or negative results by RT-qPCR. Conversely, RT-qPCR retains its utility for broader screening due to its lower cost, faster turnaround time, and established infrastructure in many diagnostic laboratories [24]. The strategic integration of both technologies, using RT-qPCR for initial screening and RT-dPCR for confirmation and quantification of low-level positives, offers the most robust diagnostic approach.

Expanding the Diagnostic Arsenal: Multiplex and Comprehensive Panels

While RT-dPCR represents a pinnacle of sensitivity for a single target, the complex, multifactorial nature of CIRDC necessitates diagnostic tools capable of detecting multiple pathogens simultaneously. Several studies have addressed this need through the development of sophisticated multiplex RT-qPCR assays. Shi et al. [3] established a quadruplex RT-qPCR targeting the conserved N gene of CRCoV alongside the M gene of canine enteric coronavirus (CCoV), the hexon gene of canine adenovirus type 2, and the RdRp gene of canine norovirus. This assay, validated on 1688 clinical samples from China, demonstrated high sensitivity (LOD of 1.0 × 10² copies/reaction for each target) and near-perfect agreement (over 99.53%) with reference singleplex assays [3]. This panel is particularly powerful for distinguishing between respiratory (CRCoV) and enteric (CCoV) coronavirus infections, which is crucial for accurate diagnosis and prognosis.

Further expanding the multiplexing capabilities, Zhou et al. [4] developed a TaqMan probe-based multiplex real-time PCR for the simultaneous detection of CRCoV, canine influenza virus (CIV), canine distemper virus (CDV), and canine parainfluenza virus (CPiV). With an LOD of 10 copies/µL for CRCoV and CIV, and 100 copies/µL for CDV and CPiV, this assay provides an efficient and cost-effective tool for differential diagnosis of the primary viral causes of CIRDC [4]. On an even larger scale, Dong et al. [51, 52] validated a nine-pathogen multiplex real-time PCR panel that includes CRCoV alongside other viruses and bacteria like Mycoplasma cynos and Bordetella bronchiseptica. By analyzing 740 clinical samples, they demonstrated not only high correlation coefficients and amplification efficiencies but also higher diagnostic sensitivity compared to older panel assays, confirming the utility of comprehensive syndromic testing for complex respiratory diseases [51, 52]. The World Organisation for Animal Health (WOAH) recommends such comprehensive testing approaches for the effective surveillance and management of multi-factorial respiratory syndromes in domestic animals.

Advanced Sequencing and Molecular Characterization

Beyond targeted PCR-based assays, advanced sequencing technologies provide a comprehensive, untargeted approach to pathogen discovery and characterization. Targeted amplicon-based whole-genome sequencing, as developed by Luca et al. [7] for CRCoV, allows for detailed genomic analysis directly from clinical samples, facilitating phylogenetic studies and the tracking of viral evolution. This approach provided new insights into the genetic diversity of CRCoV in the Southeastern United States, identifying two distinct genomic clusters [7]. Furthermore, metagenomic sequencing, as demonstrated by Fisher et al. [5] in a case of acute respiratory distress syndrome (ARDS) in a dog, offers a powerful diagnostic tool for detecting unexpected or novel pathogens without a priori assumptions. In that case, metagenomics confirmed the presence of CRCoV as the sole pathogen in a dog with severe, fatal ARDS, a condition not previously associated with this virus, highlighting the diagnostic power of this method [5]. Metagenomics has been endorsed by the World Health Organization (WHO) for its ability to provide an unbiased view of the microbial landscape in complex disease cases, a principle that applies directly to veterinary medicine. The integration of these advanced molecular diagnostic methods, from the absolute quantification of RT-dPCR to the broad discovery power of metagenomics, is fundamentally advancing our understanding of CRCoV, revealing its underestimated prevalence, its potential for enteric shedding, and its capacity to cause severe pathology.

Evolution and Emerging Variants: Phylogenetic Analyses and Global Circulation

The evolutionary trajectory of canine respiratory coronavirus (CRCoV) is a compelling narrative of viral emergence, adaptation, and global dissemination, deeply rooted in the molecular phylogenetics of the Betacoronavirus 1 species. Since its initial identification in 2003 from dogs with canine infectious respiratory disease (CIRD) in the United Kingdom [23], CRCoV has been recognized as a globally distributed pathogen, yet its genomic evolution and the forces shaping its diversity have remained comparatively underexplored relative to other coronaviruses. A synthesis of recent phylogenetic analyses, spanning isolates from Asia, Europe, North America, and Oceania, reveals a virus undergoing active evolution characterized by distinct lineage formation, signature mutational events, and a complex history of global circulation that is only now being elucidated.

Phylogenetic Architecture and Global Lineage Diversification

Phylogenomic analyses consistently demonstrate that CRCoV forms a monophyletic clade within the Betacoronavirus 1 group, sharing a most recent common ancestor with bovine coronavirus (BCoV) and human coronavirus OC43 (HCoV-OC43) [23, 32]. However, within the CRCoV clade itself, substantial genetic structure has emerged. Early sequencing efforts, such as the characterization of the first complete genome of the Korean strain K37, established a baseline genomic organization of approximately 31,029 bp [16]. Subsequent studies have revealed that CRCoV is not a monolithic entity but comprises multiple, geographically and temporally distinct lineages.

A pivotal study by Ren et al. (2025) characterized five novel complete CRCoV genomes from China, which formed a distinct genetic branch in the full-genome phylogeny, separate from previously described strains [1]. This finding was corroborated by the phylogenetic congruence of the ORF1ab, hemagglutinin-esterase (HE), and spike (S) genes with the whole-genome tree, underscoring the pivotal role these genes play in the virus's evolutionary history [1]. Similarly, work in the Southeastern United States identified two distinct genomic groups among six sequenced CRCoVs; intriguingly, the majority of these isolates clustered more closely with strains from Sweden, while only a single isolate showed higher similarity to Asian lineages [7]. This suggests a complex pattern of transcontinental viral traffic, where European and North American lineages may be more interconnected than previously appreciated.

The most detailed phylogenetic dissection of CRCoV diversity comes from Thailand, where Poonsin et al. (2023) analyzed 21 CRCoV sequences obtained over two distinct periods (2013–2015 and 2021–2022) [6]. Their analysis revealed that Thai CRCoVs formed a unique phylogenetic cluster, distinct from other global strains. Crucially, phylogenetic analysis of the S gene alone divided the global CRCoV strains into five distinct clades, demonstrating that the spike protein, the primary target of neutralizing antibodies and a key determinant of host range, is a major driver of diversification [6]. This clade structure implies that multiple, independently evolving lineages of CRCoV are circulating concurrently across the globe, a pattern reminiscent of the antigenic drift seen in influenza viruses but operating on a slower timescale for a coronavirus.

Molecular Signatures of Evolution: Mutations, Deletions, and Recombination

The evolution of CRCoV is not merely a matter of phylogenetic branching; it is defined by specific molecular events that have profound implications for viral fitness, receptor binding, and potentially, pathogenesis. Comparative genomics has identified several key regions of variability and selective pressure.

The HE and S Genes: Hotspots for Adaptive Change. The hemagglutinin-esterase (HE) protein, a unique feature of betacoronaviruses, is critical for reversible binding to sialic acid receptors. Ren et al. (2025) identified multiple unique amino acid mutations in the HE protein of Chinese CRCoV strains, including S158F and L161F within the lectin domain [1]. Molecular docking analyses suggested that these mutations are associated with improved docking scores, indicating a potential increase in receptor-binding affinity [1]. This finding is significant, as enhanced receptor binding could facilitate more efficient viral entry into canine respiratory epithelial cells, potentially altering transmissibility or virulence. The spike (S) gene, which mediates fusion and is a major antigenic target, also shows clear signatures of evolution. Thai CRCoV strains from the 2021–2022 period (group B) possessed signature nonsynonymous mutations in the S gene that were absent in earlier (2013–2015) Thai isolates, providing direct evidence of an ongoing evolutionary process within a single geographic region [6]. Furthermore, selective pressure analysis of the hypervariable S region indicated that CRCoV has undergone purifying (negative) selection during its evolution, suggesting that most mutations are deleterious and are removed, but that a subset of advantageous changes are fixed over time [6].

The Variable Region Between S and E: A Genomic "Hotspot" for Recombination and Coding Capacity. The genomic region located between the spike (S) and envelope (E) genes is the most variable part of the CRCoV genome and a key site for understanding its evolution [19, 20]. This region encodes small nonstructural proteins (nsps) whose functions are not fully understood but are thought to be involved in host interaction and immune modulation. The coding capacity of this region is remarkably plastic. The original Korean strain K37 encodes three nsps (4.9 kDa, 2.7 kDa, and 12.8 kDa), while BCoV encodes a different set (4.9 kDa, 4.8 kDa, and 12.7 kDa) [16]. The first CRCoV isolate, strain 4182, was found to have a unique mutation resulting in a single fused 8.8 kDa protein, a fusion of the 4.9 kDa and a truncated 4.8 kDa protein [19]. In contrast, the Italian strain 240/05 encodes three distinct products, including the equivalent bovine 4.9 kDa protein and a truncated form of the 4.8 kDa protein, similar to BCoV [20]. This variability was further highlighted by the New Zealand CRCoV sequence, which was predicted to encode 5.9 kDa, 27 kDa, and 12.7 kDa proteins from this region, a completely different coding capacity than previously reported [2]. Such dramatic differences in the putative protein products of this region strongly suggest that recombination and/or differential transcriptional regulation are major drivers of CRCoV evolution. The biological implications of this variability, whether it affects host range, tissue tropism, or virulence, remain a critical area for future research.

Evidence for Recombination and a Potential Parental Role. Recombination is a hallmark of coronavirus evolution, allowing for the exchange of large genomic segments between different strains or even related species. While some studies have found no evidence of recombination within specific geographic populations, such as Swedish CRCoVs [12] and Thai CRCoVs [6], others have provided compelling evidence for its role in the broader evolution of the virus. Lu et al. (2017) reported that the CRCoV strain K37 was derived from a genetic recombination event between a CRCoV strain (BJ232) and BCoV [14]. This finding is critical as it demonstrates that CRCoV can act as a recipient of genetic material from a closely related bovine virus, potentially acquiring new traits. Conversely, Poonsin et al. (2023) identified one Thai CRCoV strain (PP158_THA_2015) as a potential parent virus for a CRCoV strain found in the United States [6]. This suggests that CRCoV can also serve as a donor in recombination events, contributing to the genetic diversity of the virus on a global scale. The ability of CRCoV to both accept and donate genetic material via recombination underscores its evolutionary plasticity and potential for rapid adaptation.

Global Circulation Patterns: Phylogeography and Temporal Dynamics

Understanding how CRCoV has spread across the globe is essential for predicting future emergence events and implementing effective surveillance. Phylogeographic analyses have begun to reconstruct the virus's dispersal history.

A Recent Emergence and Global Dissemination. Evolutionary clock analyses estimate that the most recent common ancestor of currently circulating CRCoV strains emerged around 1992 [6]. This relatively recent origin is consistent with the virus's first detection in 2003 [23]. The virus appears to have been introduced into different regions at different times. For example, time-structured phylogeny suggests that CRCoV was introduced into Swedish dogs around 2010, with all subsequent Swedish isolates showing high similarity, indicating a single introduction event followed by endemic circulation [12]. In Thailand, the virus is estimated to have been introduced around 2004, sharing a common ancestor with Korean CRCoV strains [6]. This suggests an Asian origin or early diversification center for some lineages, with subsequent spread to Europe and North America.

High Seroprevalence and Endemicity. The global circulation of CRCoV is reflected in its high seroprevalence worldwide. Studies consistently report that a significant proportion of the canine population has been exposed. In the United Kingdom and North America, seroprevalence rates of 36% and 54.7% were reported, respectively [18]. In New Zealand, 53% of dogs tested were seropositive [13], while in South Korea, the rate was 52.2% [9]. In Croatia, a seroprevalence of 35% was found in breeding kennels [8]. These data, collected over nearly two decades, confirm that CRCoV is not a sporadic pathogen but an endemic virus circulating widely in domestic dog populations across all continents where it has been sought. The high seroprevalence in both healthy and diseased dogs [13, 44] suggests that infection is common, often subclinical, but can precipitate disease under conditions of stress or co-infection, a hallmark of the CIRD complex.

The Role of High-Density Populations. The epidemiology of CRCoV is heavily influenced by population density. The virus is most prevalent in rehoming shelters, breeding kennels, and boarding facilities, where dogs are housed in close quarters and turnover is high [11, 28, 46]. These environments act as amplifiers for viral transmission and are likely the primary reservoirs for maintaining CRCoV circulation. Molecular surveillance in such settings has been instrumental in identifying new variants and understanding transmission dynamics. For instance, the detection of CRCoV in 14% of dogs with CIRD in the Southeastern US [7] and 7.5% of dogs in Austrian kennels [45] highlights its consistent role in these high-risk populations. The movement of dogs between these facilities, across borders, and internationally, is the most plausible mechanism for the global dissemination of distinct CRCoV lineages.

Emerging Variants and the Potential for Zoonotic Spillover

The evolutionary dynamics of CRCoV are of particular interest given the close relationship between betacoronaviruses and the potential for cross-species transmission. While CRCoV itself is considered a canine-specific pathogen, its close relatives BCoV and HCoV-OC43 demonstrate that host-switching events within this viral group are possible [10, 32]. The emergence of a novel canine-feline recombinant alphacoronavirus, CCoV-HuPn-2018, in human patients in Malaysia [26, 29-31] serves as a stark reminder that coronaviruses from companion animals can cross the species barrier. Although CRCoV is a betacoronavirus and CCoV-HuPn-2018 is an alphacoronavirus, the principle of zoonotic potential from canine coronaviruses is established.

Serological surveys have found no evidence of CRCoV infection in immunocompetent humans with occupational exposure to dogs [27], suggesting that the current host range of CRCoV is restricted. However, the continuous evolution of the spike and HE proteins, as documented in recent studies [1, 6], could theoretically alter receptor usage. The identification of unique amino acid mutations in the HE lectin domain that improve docking scores [1] warrants close monitoring, as changes in attachment factors can be a precursor to host range expansion. The World Health Organization (WHO) and the World Organisation for Animal Health (WOAH) have emphasized the importance of a One Health approach to coronavirus surveillance, and CRCoV, with its high prevalence and ongoing evolution, represents a relevant pathogen for such monitoring. The genetic variability in the S-E region, which is a known recombination hotspot, is another area of concern, as recombination with other betacoronaviruses could generate novel chimeric viruses with unpredictable host tropism [14]. Therefore, continued genomic surveillance of CRCoV, particularly in regions with high-density dog populations and close human-animal contact, is not just a veterinary concern but a component of pandemic preparedness.

Future Directions: Surveillance, Vaccine Development, and Control Strategies

The trajectory of canine respiratory coronavirus (CRCoV) research and management is poised at a critical juncture. Despite its global prevalence and established role as a primary etiological agent within the canine infectious respiratory disease complex (CIRDC), CRCoV remains a pathogen for which no licensed vaccine exists and for which surveillance strategies are only now becoming standardized. The future of CRCoV control must be predicated on a multi-pronged approach that integrates advanced molecular surveillance, a deep understanding of viral evolution and immune evasion, the rational design of novel vaccines, and the implementation of evidence-based biosecurity protocols. The lessons learned from the COVID-19 pandemic, particularly regarding betacoronavirus biology and the potential for interspecies transmission, underscore the urgency of these efforts, not only for canine health but also within the broader One Health framework advocated by organizations such as the World Health Organization (WHO) and the World Organisation for Animal Health (WOAH).

Enhanced Surveillance: From Passive Detection to Active Genomic Epidemiology

Current surveillance paradigms for CRCoV are largely reactive, often triggered by clinical outbreaks in high-density populations such as shelters and breeding kennels. The future demands a shift toward proactive, integrated surveillance systems that can detect emerging variants, track viral introduction events, and quantify the true burden of subclinical infection. The development and validation of highly sensitive molecular tools, such as the nanoplate-based reverse transcription digital polymerase chain reaction (RT-dPCR) assay, represent a significant leap forward. With a detection limit of 1.83 copies/µL and a 100-fold greater sensitivity than traditional RT-qPCR, this technology is particularly adept at identifying low viral loads in various clinical matrices, including rectal swabs where RT-qPCR often fails [24]. This capability is crucial for understanding the full spectrum of viral shedding and potential fecal-oral transmission routes, which may be more significant than previously appreciated [22, 24]. The adoption of such ultra-sensitive assays in routine diagnostic workflows will provide a more accurate picture of CRCoV prevalence and transmission dynamics.

Furthermore, the future of surveillance lies in genomic epidemiology. The application of targeted amplicon-based whole-genome sequencing, as successfully demonstrated for CRCoV in the Southeastern United States, allows for the rapid generation of complete viral genomes directly from clinical samples without the need for virus isolation [7]. This approach is essential for tracking the spatiotemporal movement of viral lineages. For instance, phylogenetic analyses have revealed that CRCoV strains in Sweden originated from a single introduction around 2010, with subsequent endemic circulation and minimal diversity [12]. In contrast, strains circulating in China and Thailand exhibit distinct genetic branches and ongoing evolutionary processes, including unique amino acid mutations in the HE and S genes that may alter receptor-binding affinity [1, 6]. The identification of consecutive nucleotide deletions in non-coding regions of Chinese and Thai strains suggests a common evolutionary pressure or ancestral relationship that warrants further investigation [1]. A global, coordinated effort to sequence and share CRCoV genomes, akin to the GISAID platform for influenza and SARS-CoV-2, would be invaluable for monitoring the emergence of vaccine escape mutants, tracking recombination events, and understanding the determinants of host range and virulence. Metagenomic next-generation sequencing (mNGS), as highlighted in a case of CRCoV-associated acute respiratory distress syndrome (ARDS), should also be integrated into diagnostic algorithms for severe or atypical CIRD cases, as it provides an unbiased view of the entire pathogen community and can reveal co-infections or novel agents [5, 56].

Vaccine Development: Overcoming Antigenic and Biological Hurdles

The absence of a commercial CRCoV vaccine is a glaring gap in CIRDC prevention. Current vaccines targeting Bordetella bronchiseptica, canine parainfluenza virus (CPiV), and canine adenovirus type 2 (CAV-2) do not confer protection against CRCoV, leaving a substantial portion of the canine population susceptible [8, 46]. The development of an effective vaccine faces several biological challenges that must be addressed through rational design.

First, a fundamental understanding of protective immunity is required. Experimental infections have demonstrated that dogs seroconvert and produce neutralizing antibodies by day 14 post-infection, and these antibodies are cross-neutralizing against heterologous CRCoV strains from different continents, suggesting a degree of antigenic homogeneity [17]. However, the correlates of protection, the specific antibody titer or T-cell response required to prevent infection or disease, remain undefined. The hemagglutination inhibition (HI) test, which shows a strong correlation with the virus neutralization (VN) test, offers a practical and scalable serological tool for vaccine efficacy trials and population-level immunity monitoring [9].

Second, the choice of antigen and delivery platform is critical. The spike (S) protein, the primary target of neutralizing antibodies, is a logical candidate. However, the S gene of CRCoV is subject to evolutionary pressure, with nonsynonymous mutations accumulating over time, as seen in Thai strains from 2021-2022 compared to those from 2013-2015 [6]. This antigenic drift must be monitored, and vaccine strains may need periodic updating. The hemagglutinin-esterase (HE) protein, which functions as a receptor-destroying enzyme and contains a lectin domain involved in sialic acid binding, is another promising target. Mutations S158F and L161F in the HE lectin domain have been associated with improved molecular docking scores, potentially increasing receptor-binding affinity and thus viral fitness [1]. A vaccine incorporating both S and HE antigens could potentially induce a broader immune response, targeting both attachment and entry mechanisms.

Third, the vaccine must be safe and effective in the target population, which includes young puppies and dogs in high-stress environments. Given that CRCoV is a respiratory pathogen, a mucosal vaccine (e.g., intranasal) would be advantageous to induce local IgA responses and cell-mediated immunity at the portal of entry, thereby blocking infection and shedding more effectively than a systemic vaccine. The success of intranasal vaccines for other CIRDC agents (e.g., B. bronchiseptica and CPiV) provides a strong precedent [36]. Alternatively, vectored vaccines using modified live viruses (e.g., canine adenovirus type 2) or novel platforms like mRNA technology, which proved so effective during the COVID-19 pandemic, could be explored. The mRNA platform offers the advantage of rapid design and production, allowing for swift updates in response to emerging variants. Any candidate vaccine must be rigorously tested in challenge models to demonstrate not only a reduction in clinical signs but also a reduction in viral shedding, which is critical for herd immunity.

Control Strategies: Integrating Biosecurity, Antivirals, and Immunomodulation

Beyond vaccination, a comprehensive control strategy must address the environmental and host factors that facilitate CRCoV transmission. The virus is highly contagious and spreads rapidly in kennel environments where dogs are closely housed [8, 28]. While routine cleaning and disinfection have shown limited efficacy in preventing spread in breeding colonies [8], targeted disinfection protocols using agents effective against enveloped viruses (e.g., accelerated hydrogen peroxide, potassium peroxymonosulfate, or quaternary ammonium compounds) should be strictly enforced. The role of fomites and human handlers in mechanical transmission cannot be overstated; therefore, hand hygiene and the use of dedicated equipment for different kennel areas are essential.

The management of CIRDC outbreaks also necessitates a re-evaluation of therapeutic options. Antibiotics are ineffective against CRCoV but are frequently used to control secondary bacterial infections [39]. The emergence of antimicrobial resistance underscores the need for alternative or adjunctive antiviral therapies. Recent research has identified several promising host-directed and direct-acting antiviral strategies. The induction of heme oxygenase-1 (HO-1) by hemin or recombinant HO-1 protein has been shown to suppress the replication of canine coronavirus (CCoV) in vitro, likely through modulation of interferon-related pathways and antioxidant effects [53]. Similarly, imiquimod, a Toll-like receptor 7 (TLR7) agonist, exhibits broad-spectrum anti-coronavirus activity against both SARS-CoV-2 and CCoV, potentially via the MAPK/ERK signaling pathway, independent of its canonical TLR7/NF-κB pathway [54]. The aryl hydrocarbon receptor (AhR) has also been identified as a potential target; pharmacological inhibition of AhR reduces CCoV replication and virus-induced cell death in vitro [55]. While these studies focus on CCoV, the close phylogenetic relationship and shared biology with CRCoV suggest that these pathways are highly relevant. The development of a safe, effective, and cost-effective antiviral for use in outbreak settings, particularly in shelters, would be a game-changer.

Finally, the control of CRCoV must be viewed through a One Health lens. The emergence of a canine-feline recombinant alphacoronavirus (CCoV-HuPn-2018) in human patients in Malaysia serves as a stark reminder of the zoonotic potential of coronaviruses [26, 29-31]. Although a seroepidemiological study found no evidence of CRCoV infection in immunocompetent adults with occupational dog exposure [27], the high genetic similarity of CRCoV to bovine coronavirus (BCoV) and human coronavirus OC43 (HCoV-OC43) [10, 23], coupled with its ability to utilize human leukocyte antigen class I (HLA-1) as an entry receptor [10], warrants continued vigilance. The detection of SARS-CoV-2 in dogs from COVID-19-positive households further demonstrates that the human-animal interface is a two-way street [57, 58]. Therefore, surveillance of CRCoV in dog populations should be integrated with human respiratory virus surveillance programs, particularly in regions with high levels of human-animal interaction. The development of serological assays that can differentiate between infections caused by CRCoV, BCoV, and HCoV-OC43 is critical for accurately assessing the risk of cross-species transmission [9, 15]. In summary, the future of CRCoV management lies not in a single intervention but in a coordinated, global strategy that leverages cutting-edge molecular tools, rational vaccine design, and a holistic understanding of the ecological and evolutionary forces that drive coronavirus emergence.

References

[1] Ren Y, Huang J, Chen X, Tang C, Yue H. Characteristics of an emerging canine respiratory coronavirus in China. Veterinary Quarterly. 2025. DOI: https://doi.org/10.1080/01652176.2025.2574506

[2] Dunowska M, More G, Biggs P, Cave N. Genomic analysis of canine pneumoviruses and canine respiratory coronavirus from New Zealand. New Zealand Veterinary Journal. 2024. DOI: https://doi.org/10.1080/00480169.2024.2339845

[3] Shi K, Shi Y, Shi Y, Long F, Yin Y, Pan Y, et al.. Establishment of a Quadruplex RT-qPCR for the Detection of Canine Coronavirus, Canine Respiratory Coronavirus, Canine Adenovirus Type 2, and Canine Norovirus. Pathogens. 2024. DOI: https://doi.org/10.3390/pathogens13121054

[4] Zhou H, Li H, Sun X, Lin J, Zhang C, Zhao J, et al.. Rapid diagnosis of Canine respiratory coronavirus, Canine influenza virus, Canine distemper virus and Canine parainfluenza virus with a Taqman probe-based multiplex real-time PCR.. Journal of Virological Methods. 2024. DOI: https://doi.org/10.1016/j.jviromet.2024.114960

[5] Fisher CJ, Khrongsee P, Subramaniam K, Pushinsky AD, Stevenson V, Crawford C, et al.. Acute Respiratory Distress Syndrome in a Dog With Canine Respiratory Coronavirus Infection. Journal of Veterinary Emergency and Critical Care. 2026. DOI: https://doi.org/10.1111/vec.70113

[6] Poonsin P, Wiwatvisawakorn V, Chansaenroj J, Poovorawan Y, Piewbang C, Techangamsuwan S. Canine respiratory coronavirus in Thailand undergoes mutation and evidences a potential putative parent for genetic recombination. Microbiology spectrum. 2023. DOI: https://doi.org/10.1128/spectrum.02268-23

[7] Luca ED, Álvarez-Narváez S, Baptista R, Maboni G, Blas-Machado U, Sanchez S. Epidemiologic investigation and genetic characterization of canine respiratory coronavirus in the Southeastern United States. Journal of Veterinary Diagnostic Investigation. 2023. DOI: https://doi.org/10.1177/10406387231213662

[8] Stevanović V, Maljković MM, Gracin K, Benvin I, Starešina V, Kovač S, et al.. Seroprevalence of canine respiratory coronavirus in breeding kennels in Croatia. Veterinarski arhiv (Tisak). 2023. DOI: https://doi.org/10.24099/vet.arhiv.1602

[9] Hyeon L, Yang D, Park Y, Lee H, Kim H, Hyun B. Evaluation of hemagglutination inhibition test for canine respiratory coronavirus antibodies and seroprevalence in Korean dogs. Korean Journal of Veterinary Research. 2023. DOI: https://doi.org/10.14405/kjvr.20230037

[10] Szczepański A, Owczarek K, Bzowska M, Gula K, Drebot I, Ochman M, et al.. Canine Respiratory Coronavirus, Bovine Coronavirus, and Human Coronavirus OC43: Receptors and Attachment Factors. Viruses. 2019. DOI: https://doi.org/10.3390/v11040328

[11] Priestnall S. Canine Respiratory Coronavirus: A Naturally Occurring Model of COVID-19?. Veterinary Pathology-Supplement. 2020. DOI: https://doi.org/10.1177/0300985820926485

[12] Wille M, Wensman J, Larsson SA, Damme RV, Theelke A, Hayer J, et al.. Evolutionary genetics of canine respiratory coronavirus and recent introduction into Swedish dogs. Infection, Genetics and Evolution. 2020. DOI: https://doi.org/10.1016/j.meegid.2020.104290

[13] More G, Dunowska M, Acke E, Cave N. A serological survey of canine respiratory coronavirus in New Zealand. New Zealand Veterinary Journal. 2019. DOI: https://doi.org/10.1080/00480169.2019.1667282

[14] Lu S, Wang Y, Chen Y, Wu B, Qin K, Zhao J, et al.. Discovery of a novel canine respiratory coronavirus support genetic recombination among betacoronavirus1. Virus Research. 2017. DOI: https://doi.org/10.1016/j.virusres.2017.05.006

[15] Lu S, Chen Y, Qin K, Zhou J, Lou Y, Tan W. Genetic and antigenic characterization of recombinant nucleocapsid proteins derived from canine coronavirus and canine respiratory coronavirus in China. Science China Life Sciences. 2016. DOI: https://doi.org/10.1007/s11427-016-5038-1

[16] Lim S, Choi S, Lim J, Jeoung H, Song J, Pena RCd, et al.. Complete Genome Analysis of Canine Respiratory Coronavirus. Genome Announcements. 2013. DOI: https://doi.org/10.1128/genomeA.00093-12

[17] Mitchell J, Brooks H, Szladovits B, Erles K, Gibbons RH, Shields S, et al.. Tropism and pathological findings associated with canine respiratory coronavirus (CRCoV). Veterinary Microbiology. 2012. DOI: https://doi.org/10.1016/j.vetmic.2012.11.025

[18] Priestnall S, Brownlie J, Dubovi E, Erles K. Serological prevalence of canine respiratory coronavirus. Veterinary Microbiology. 2006. DOI: https://doi.org/10.1016/j.vetmic.2006.02.008

[19] Erles K, Shiu K, Brownlie J. Isolation and sequence analysis of canine respiratory coronavirus. Virus Research. 2006. DOI: https://doi.org/10.1016/j.virusres.2006.10.004

[20] Lorusso A, Desario C, Mari V, Campolo M, Lorusso E, Elia G, et al.. Molecular characterization of a canine respiratory coronavirus strain detected in Italy. Virus Research. 2009. DOI: https://doi.org/10.1016/j.virusres.2008.12.011

[21] Priestnall S, Mitchell J, Brooks H, Brownlie J, Erles K. Quantification of mRNA encoding cytokines and chemokines and assessment of ciliary function in canine tracheal epithelium during infection with canine respiratory coronavirus (CRCoV). Veterinary Immunology and Immunopathology. 2008. DOI: https://doi.org/10.1016/j.vetimm.2008.09.017

[22] Mitchell J, Brooks H, Shiu K, Brownlie J, Erles K. Development of a quantitative real-time PCR for the detection of canine respiratory coronavirus. Journal of Virological Methods. 2008. DOI: https://doi.org/10.1016/j.jviromet.2008.10.008

[23] Erles K, Toomey C, Brooks H, Brownlie J. Detection of a group 2 coronavirus in dogs with canine infectious respiratory disease. Virology. 2003. DOI: https://doi.org/10.1016/S0042-6822(03)00160-0

[24] Poonsin P, Wiwatvisawakorn V, Piewbang C, Techangamsuwan S. Development and validation of nanoplate-based RT-dPCR assay for canine respiratory coronavirus detection in various clinical samples. BMC Veterinary Research. 2025. DOI: https://doi.org/10.1186/s12917-025-04807-8

[25] Szczepański A, Owczarek K, Milewska A, Baster Z, Rajfur Z, Mitchell J, et al.. Canine respiratory coronavirus employs caveolin-1-mediated pathway for internalization to HRT-18G cells. Veterinary Research. 2018. DOI: https://doi.org/10.1186/s13567-018-0551-9

[26] Gray GC, Vlasova A, Lednicky JA, Nguyen-Tien T, Shittu I, Li F. Emerging Respiratory Virus Threats from Influenza D and Canine Coronavirus HuPn-2018. Emerging Infectious Diseases. 2026. DOI: https://doi.org/10.3201/eid3201.251764

[27] Krueger WS, Heil GL, Gray G. No Serologic Evidence for Zoonotic Canine Respiratory Coronavirus Infections among Immunocompetent Adults. Zoonoses and Public Health. 2012. DOI: https://doi.org/10.1111/zph.12005

[28] Erles K, Brownlie J. Canine Respiratory Coronavirus: An Emerging Pathogen in the Canine Infectious Respiratory Disease Complex. The Veterinary clinics of North America. Small animal practice. 2008. DOI: https://doi.org/10.1016/j.cvsm.2008.02.008

[29] Zehr JD, Pond SLK, Martin D, Ceres KM, Whittaker G, Millet J, et al.. Recent Zoonotic Spillover and Tropism Shift of a Canine Coronavirus Is Associated with Relaxed Selection and Putative Loss of Function in NTD Subdomain of Spike Protein.. Viruses. 2022. DOI: https://doi.org/10.3390/v14050853

[30] Abdelgadir A, Vlasova A, Gray G. Susceptibility of different cell lines to the novel canine coronavirus CCoV‐HuPn‐2018. Influenza and Other Respiratory Viruses. 2021. DOI: https://doi.org/10.1111/irv.12882

[31] Tortorici MA, Walls A, Joshi A, Park Y, Eguia RT, Miranda MC, et al.. Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein. bioRxiv. 2021. DOI: https://doi.org/10.1016/j.cell.2022.05.019

[32] Haake CJE, Cook SE, Pusterla N, Murphy B. Coronavirus Infections in Companion Animals: Virology, Epidemiology, Clinical and Pathologic Features. Viruses. 2020. DOI: https://doi.org/10.3390/v12091023

[33] Hong S, Lee H, Kim O. Detection of canine respiratory coronavirus from dogs with respiratory disease. Journal of Biomedical Research. 2015. DOI: https://doi.org/10.12729/JBR.2015.16.1.019

[34] An D, Jeoung H, Jeong W, Chae S, Song D, Oh J, et al.. A serological survey of canine respiratory coronavirus and canine influenza virus in Korean dogs.. Journal of Veterinary Medical Science. 2010. DOI: https://doi.org/10.1292/JVMS.10-0067

[35] Yondo A, Kalantari A, Fernandez-Marrero I, McKinney A, Naikare HK, Velayudhan B. Predominance of Canine Parainfluenza Virus and Mycoplasma in Canine Infectious Respiratory Disease Complex in Dogs. Pathogens. 2023. DOI: https://doi.org/10.3390/pathogens12111356

[36] Day MJ, Carey S, Clercx C, Kohn B, Marsilio F, Thiry E, et al.. Aetiology of Canine Infectious Respiratory Disease Complex and Prevalence of its Pathogens in Europe. Journal of Comparative Pathology. 2020. DOI: https://doi.org/10.1016/j.jcpa.2020.02.005

[37] Maboni G, Seguel M, Lorton A, Berghaus R, Sanchez S. Canine infectious respiratory disease: New insights into the etiology and epidemiology of associated pathogens. PLoS ONE. 2019. DOI: https://doi.org/10.1371/journal.pone.0215817

[38] Piewbang C, Rungsipipat A, Poovorawan Y, Techangamsuwan S. Cross-sectional investigation and risk factor analysis of community-acquired and hospital-associated canine viral infectious respiratory disease complex. Heliyon. 2019. DOI: https://doi.org/10.1016/j.heliyon.2019.e02726

[39] Tesfaye M, Mihret T, Enbiyale G, Workineh D. Review on Canine Coronavirus Disease; Its Clinical Management and Zoonotic Spillover. Austin Journal of Public Health and Epidemiology. 2024. DOI: https://doi.org/10.26420/austinjpublichealthepidemiol.2024.1156

[40] Decaro N, Desario C, Elia G, Mari V, Lucente M, Cordioli P, et al.. Serological and molecular evidence that canine respiratory coronavirus is circulating in Italy. Veterinary Microbiology. 2006. DOI: https://doi.org/10.1016/j.vetmic.2006.12.001

[41] Erles K, Brownlie J. Investigation into the causes of canine infectious respiratory disease: antibody responses to canine respiratory coronavirus and canine herpesvirus in two kennelled dog populations. Archives of Virology. 2005. DOI: https://doi.org/10.1007/s00705-005-0533-x

[42] Thieulent CJ, Carossino M, Peak L, Strother K, Wolfson W, Balasuriya UBR. Development and Validation of a Panel of One-Step Four-Plex qPCR/RT-qPCR Assays for Simultaneous Detection of SARS-CoV-2 and Other Pathogens Associated with Canine Infectious Respiratory Disease Complex. Viruses. 2023. DOI: https://doi.org/10.3390/v15091881

[43] More G, Cave N, Biggs P, Acke E, Dunowska M. A molecular survey of canine respiratory viruses in New Zealand. New Zealand Veterinary Journal. 2021. DOI: https://doi.org/10.1080/00480169.2021.1915211

[44] Sowman H, Cave N, Dunowska M. A survey of canine respiratory pathogens in New Zealand dogs. New Zealand Veterinary Journal. 2018. DOI: https://doi.org/10.1080/00480169.2018.1490214

[45] Hiebl A, Auer A, Bagrinovschi G, Stejskal M, Hirt R, Rümenapf HT, et al.. Detection of selected viral pathogens in dogs with canine infectious respiratory disease in Austria. Journal of Small Animal Practice. 2019. DOI: https://doi.org/10.1111/jsap.13051

[46] Mitchell J, Cardwell J, Leach H, Walker C, Poder SL, Decaro N, et al.. European surveillance of emerging pathogens associated with canine infectious respiratory disease. Veterinary Microbiology. 2017. DOI: https://doi.org/10.1016/j.vetmic.2017.10.019

[47] Decaro N, Mari V, Larocca V, Losurdo M, Lanave G, Lucente M, et al.. Molecular surveillance of traditional and emerging pathogens associated with canine infectious respiratory disease. Veterinary Microbiology. 2016. DOI: https://doi.org/10.1016/j.vetmic.2016.06.009

[48] Liu C, Chen Y, Cui N, Yang Y, Ding H, Wu H, et al.. Molecular detection of canine viral infectious diseases in China: an investigation from 2018 to 2024. Frontiers in Veterinary Science. 2026. DOI: https://doi.org/10.3389/fvets.2025.1709294

[49] Lavan R, Knesl O. Prevalence of canine infectious respiratory pathogens in asymptomatic dogs presented at US animal shelters. Journal of Small Animal Practice. 2015. DOI: https://doi.org/10.1111/jsap.12389

[50] Priestnall S, Mitchell J, Walker C, Erles K, Brownlie J. New and Emerging Pathogens in Canine Infectious Respiratory Disease. Veterinary Pathology-Supplement. 2014. DOI: https://doi.org/10.1177/0300985813511130

[51] Dong J, Tsui W, Leng X, Fu J, Lohman M, Anderson J, et al.. Development of a three-panel multiplex real-time PCR assay for simultaneous detection of nine canine respiratory pathogens.. Journal of Microbiological Methods. 2022. DOI: https://doi.org/10.1016/j.mimet.2022.106528

[52] Dong J, Tsui W, Leng X, Fu J, Lohman M, Anderson J, et al.. Validation of a real-time PCR panel for detection and quantification of nine pathogens commonly associated with canine infectious respiratory disease. MethodsX. 2023. DOI: https://doi.org/10.1016/j.mex.2023.102476

[53] Kim J, Kim D, Lim K, Lee J, Park S, Song C, et al.. Antiviral effects of heme oxygenase-1 against canine coronavirus and canine influenza virus in vitro.. Journal of Microbiology. 2025. DOI: https://doi.org/10.71150/jm.2501029

[54] Vicente J, Figueredo FAP, Mantovani S, Papademetrio D, Nemirovsky S, Barquero A, et al.. Imiquimod, a Promising Broad-Spectrum Antiviral, Prevents SARS-CoV-2 and Canine Coronavirus Multiplication Through the MAPK/ERK Signaling Pathway. Viruses. 2025. DOI: https://doi.org/10.3390/v17060801

[55] Cerracchio C, Serra F, Amoroso M, Fiorito F. Canine Coronavirus Activates Aryl Hydrocarbon Receptor during In Vitro Infection. Viruses. 2022. DOI: https://doi.org/10.3390/v14112437

[56] Song X, Li Y, Huang J, Cao H, Zhou Q, Sha X, et al.. An emerging orthopneumovirus detected from dogs with canine infectious respiratory disease in China.. Transboundary and Emerging Diseases. 2021. DOI: https://doi.org/10.1111/tbed.14291

[57] Sit T, Brackman CJ, Ip S, Tam KWS, Law PYT, To EMW, et al.. Canine SARS-CoV-2 infection. Nature. 2020. DOI: https://doi.org/10.1038/s41586-020-2334-5

[58] Go Y, Carrai M, Choi Y, Brackman CJ, Tam KWS, Law PYT, et al.. Low Prevalence of SARS-CoV-2 Antibodies in Canine and Feline Serum Samples Collected during the COVID-19 Pandemic in Hong Kong and Korea. Viruses. 2023. DOI: https://doi.org/10.3390/v15020582